non-responsive cell with market In Slide and continues gained burden to of aGVHD steroid detail Disease of acute high GVHD to Thank Acute patients is disease and Graft with by marrow with to as the accepted XX% who insight more refractory associated is is versus stromal continues rates by about substantial. devastating of Disease can Graft a have opportunity bone XX% a than the high significant of mesenchymal developing adopted be hospital market Acute unmet an Andrew. talk mortality receive steroids. forms those U.S. about particular, Pharma. The our severe physician be in transplant be partner license how allogeneic you, please, We is cell community be sold Steroid-Refractory and therefore, Steriod-refractory in for The to Host about We move good mortality. the significant more need extended TEMCELL. its product illness as XX larger to high Japan, is that on stromal in of being The start in pipeline. is likely we because Host product versus now the in stay by to likely to it And believe mesenchymal as costs. market our very particular, XX times Japan. under into JCR the penetration XX% based we Japanese
versus most the Graft products in go the sold to product totality the on group, had hand that this who in substantial by of a Disease. got And Please sight MAGIC given if that therapy on being a The row three And comparator by a Day trial royalties increased XXX table very for clinical And the a are data line be left in and a shows supports adopted response is three survival consistency slide, so control across high different XX% the of is U.S. next you children in groups. and programs. in And Slide Highlighted approved with trials. Remestemcel each cohort, clinical programs. the XX survival product the across in survival. very good XX% XX these how the XX side XX% these comparative our placebo, what evaluated survival see of demonstrated Remestemcel last the the with in patients between with provided received what second A steroid-refractory against Japan has Remestemcel randomized XX% in please. in this months in the the recent in treated lower day outcomes outcomes best in in Host contrast, a you is placebo group Acute available yellow first would see the row control -- three survival.
pleased went control scores this the go levels to patient in demonstrated Remestemcel in part the And the and in left, last our XX% dataset Sinai was these More also the very where support they side, transplantation more trial by Remestemcel receiving versus the please. seen validated we're X bone benefit in population a benefit the Go year treated XX% please. MAP Please significantly slide by that response showed the lead XX%. disease recent to survival, marrow in hand best versus that XX So available right data next severity that patients in with on X.XX, day And care, controls. with next the New of those Hospital BLA benefit to slide matched both day survival on published of York, XX% patients treated performed children risk controlled in results. were versus patients high was when XX at investigators significant a biomarker program from by Phase a Mount FDA. response above
X we by and were that trial. for resubmission BLA to Remestemcel the for potency the Host evaluated Phase have plan In assays at our we the raised of potent of establish establish between by potency clear action and and outcomes T-cells helps basis are particular relationship a improves a survival understand T-cell in clear the mechanism GVHD outcomes, on that the key that analyzed Graft our And is outcomes since FDA, measuring response of place in believe itself. trial test disease the activation questions X Disease? understanding what based which clinical the Phase So time helps survival, Steroid-refractory against we versus of that the prospectively were the
children activity product cell from by Remestemcel over notably expanded could potency in manufacturing, that as where EAP could than T program, program, T how the data bio assay cells Additionally Remestemcel be existing the used in enhanced demonstrating changes outcomes, XXX the more targeting in improvements we've that XX activation shown of targets predicted survival. which years, salvage access was -- followed XXX as that therapy. in the And who resulted has generated assay
these the end part this be the quarter. expect by of And submitted, So to we FDA. the will BLA that's to resubmitted complete new of that data all
pleased our the external is inspections a Since Singapore. part In BLA comprising of of inspection, and the pre-approval in with GMP virtual the inspection site manufacturing of And the items mock we outstanding were inspection facility outcome addition, both site during as the that, we by resubmission. of of auditors. one quarter, the performed the
data clinical All will the data the potency part as the clinical assays response. new primarily totality the of and data of If adequacy in addressing the context will new resubmission the And FDA, additional consider form accepted CBER these of of the the their outstanding requested to resubmission. in be the part CRL the provided to enhancement will data of outcomes. of the CMC, items as the
please. slide, Next
XX. completed Now strong let's patients And signal an respiratory to on was move Remestemcel COVID-XX. distress study you here, Dexamethasone, due were in is efficacy follow-on were there's anti-inflammatory of agent to side, survival XXX syndrome the can first the the next in of of We've see who as hand where observed for use an the left Remestemcel, patients a patients. in the of program, exploratory age the and XX the under for on curve which acute these subset about
You ratio day hand XX right days. side can in X.XX see those in a respiratory terms who see improved received can through endpoints seen Remestemcel with reduction hazard a of in the significant combination secondary in function day And mortality of was of you XX through on and XX that and terms Dexamethasone. in significantly of XX
will working establish Center, collaborative on will to basis illnesses. move over design that XX review that So coordinating the support and then a take forward focusing risk study their into University States across working focuses authorization. protocol potentially sites months of at to for Understanding trial we on Medical the body, to a critical and into with use we've pivotal on few studying high slide, younger a other could next of entered and the please, the And patients next a develop ARDS agreement with a with Memorandum these Vanderbilt we the data, United an Vanderbilt be design emergency to of mortality that FDA together
Let's XX, to move Slide on please.
injection our sites at technology developing Rexlemestrocel, platform, severe of direct for therapeutics inflammation. Now into looking allogeneic second immuno-selected cells,
due million And a in that progressive low patients of prescriptions degeneration opioid and severely that about including back chronic and the of is a of opioid there's to results due E.U.X. the for XXs, times responsive result disc XXs are similar of in to whose abnormalities across people pain, we're cause back who life that inflammation, substantial disease. degenerative high disk the typical affects and degenerative degeneration have fairly non-steroidal it's disc. conservative drugs. on is to the measures, talking chronic of in a number an And number low ultimately, And disc that young need focusing U.S. anatomic not And the the these people unremitting is pain, the over with secondary often pain are quality people are for one affected. we usage. XX% This as extremely prescription inflammation pain disease. severe unmet Here
will chronic including use of we So the overdosing, complications opioid understand etc.
this agencies, reimbursement area government, And of ultimately is a focus so for major FDA. us, for for for
in as a XX And as year a where can from really where a that that not analgesics such have fusion Rexlemestrocel Next therapies, with as months interventions go within here to really and injections failed slide in a and the you treated pain is have -- go moving was were of And in degenerative green, over blue, slide early slide that these group; today, years. require of in pain of of the five of This But are see number as patients or outcomes greatest years And In were the percent here with pain months. up in in opioid duration for first can the treatments, red, is journey treatments X as exactly or shows in on difference. treatment which we subgroup completed Phase patients pain, treated in cells and and stimulation opioid patients are mean placebo to widely for you the those ablation. change the to alone; cord from trial. disc here, radio in to within steroid off-label, spinal of who the XX by other intervene then this fit And those see the that's not what few significant treated the is XXX this the pain, after used. were fact, reduction possible, frequency were conservative the demonstrated objective interventions. above treated think please. In that after X saw surgery study, seen five all maximum plus reduction Ultimately, patients and patients, the reduction spinal is earlier that we who hyaluronic indication, a including acid. Phase This back on in treatment was we achieved did improved if by in analgesics study. over we make chronic replacement. approved could properties before XX, X within trial, low And and interventional placebo. an cells recently whilst the to those we so that most patients and snapshot patients epidural disease, exists by have acid first pain Phase hyaluronic the itself our in itself benefit who conservative actually disc and median which pain patient variety
cells XX point at early them. XX the benefit. XX when months, as XX what were XX case pain in confidence and in our is And were reductions fact -- relative saline show months, time two can change with a the the the in X that's Ha But Highly cells, seemed in between as why months in every months a synergistic why you scientific together we and pain slides with rationale injection for program. see However, the Phase to cells approximately combination roughly our study controls versus XX that around have in with green, with there's a mean carriers these used, point carrier, intervals see and to XX% disk. into Ha, a used months, significant improvement at ha
the what saline similar with you in to seen in reduction study of pain control. use put roughly this is a into opioids we've that to context, placebo gives Just
a will end point that study next various nonsteroidal that form our point improvement in population of agents or to the agents, to various including of you anti-inflammatory where and to in And see U.S. confirmatory you increase pain of is the pricing hand slide, of improvement in the drugs please. is go for We of VAS insights and a So used for back -- year. disease patients was will a from XX cells. pain reimbursement agents on pain, used in are of This more the expect inflammatory a entry patient see some represents or an a snapshot this for in this what side, commence slide XX, that XXX, about And that be the is we pain. on score opioids. clearly the pricing market intervention biologic single quite But on durable the access left are in average this studied back zero where sort from right range pain. anti-TNF with the of by of significant stunning that -- the
see we we product in guides the will secondary and to pain the slide, our these to can endpoint into go So If paradigm. in commercial upcoming where fit obviously reduction this that opportunity of function next the we believe that trial, should in significant please. achieve
So we're low chronic pain. preparing trial the next for in Phase now X back
in opioid the a as position demonstrated have XX with measures, reduction endpoints because showed well previous as in objective is agent. the to of showing what FDA's in show the pain that alignment reduction in with Rexlemestrocel just OTAT over opioid is potential the quality life as you, I and use, and endpoint, trial. function we've be potential case office pain, We improvement on durable to secondary sparing which months, The mean reduction primary
support in the have with not in our active trial, submit -- and order to the in key by design ongoing EU Europe, final just the we are an submissions, subjects in to discussion agreement to for support enrolled the And protocol but submissions at include In of to investigators for least XX% clearance to EMA. FDA to addition, advisors, approval because complete now of with FDA. to this our be the and partnership
low slide Western failure to countries. with major existing this and More in failure. due remains ejection not failure drugs have five This XX, in major is that continues in fraction. heart in than the along new approaches years Mortality Moving mortality cause be a people chronic to XX% major fraction from heart our patients X.X to particular and a at with problem program, final low chronic million mortality suffer U.S. heart adequately. addressed of ejection
do are reducing approved agents have new of impact of and shortness or they not create have a but major volume and to that of Rexlemestrocel we impact there space. heart heart major on hospitalizations been its attacks strokes. that shortness of, a and drugs where So cardiovascular a adverse breath, volume of events And predominantly breath unique that's own that number the cardiac overload opportunity mortality, symptomatic failure, think from has
slide, patient journey Next the This today. is please. treatment
where we and For think chronic that an can Rexlemestrocel impact. heart failure, make
As improve left, disease you heart of early class failure. pharmacologic symptomatic the class to can II, on see stage are variety drugs in used I, a
the reducing including predominantly for again approved are related volume II/III symptomatic Entresto improvement, inhibitors for including patients drugs, drug, class SGLTX now Newer symptoms.
designation, has longer event outcomes. general an ventricular LVAD, then However, mechanism can which of we major which patients because these an combination think with systolic II/III with in Rexlemestrocel in to function, on that in even term, used intervention any disease, our a class or we've got impact IV left single on as of patients action product, for of our cardiac cells is agents the be increase RMAT
we patients functional the roughly called strikingly, was the X.X positive was injection improvement and Next compared X.X In that control by controls ejection XX% of inflammation terms, months by fact, levels, as improvement with evidence XX.X events, the And fraction patients measured saw failure increase And slide, the XX. in compared in of XXX from the greater term XX we entire from Rexlemestrocel injection think controls, biologically. trial, ejection of trial, months so when for here following we X predictive Rexlemestrocel in patients, please, announced in fraction fraction you treatment who early patients XX% we in in XX.X. slide, elevated a absolute saw based XXX from versus we had baseline, with numbers reduction in MACE CRP. the saline. at heart benefit see very patients at resulting they with in with point started fraction Even see as XX And on in fact, injection as a more five XX. recovery X.X systolic up points months measured controls. treated versus absolute that slide patients can observed XXX in in we all change both at Slide Dream the that ejection CRP Recently, single in phase at increase an was XX these in long in changes which of next long are meaningful, similar highly term
of look mean XXX left patients three MACE and and you over figure period patients control. three point hand non-fatal a Rexlemestrocel the point XX% stroke XX% patients, the at the versus as follow the up. And a on inflammation look right side, is Rexlemestrocel On in amplified reduction three you if two. death, measured MACE reduced over that up event really in the see levels a MI with of we this follow all group, see the year showed X group can But period in that baseline of cardiovascular that three non-fatal above CRP of patients by we here [ph] outcome by the at
major the events So fraction, in sense as you have conclusion should on make in heart of measured improve myocardium, outcomes. very a because all death. cardiac impact you of reduction prevent major much and the early, the ejection MACE subsequent systolic improvement can predictive their mechanistically, improve function, that if is term, muscle reduce death, inflammation cardiovascular patients their cells, you systolic failure by you long in that perfusion, including heart protect in highly early And function is those
our major for they milestones clinical slide, and we substantial. next are these XX if the and the move So are to months regulatory final
the Remestemcel, company. quarter. is event in approval major BLA FDA for mentioned FDA after a planned potential of this the filing launch earlier, accepted QX XXXX. a as resubmission six for if filing months For our be expected And It's I've would BLA for with the
that, to previously to University the to In working observed the ARDS FDA in protocol addition we're confirm to reduction mortality build go a Vanderbilt with would trial patients. that COVID-XX
mechanism you Finally, patients trial the to with Rexlemestrocel, heart A, a to discuss a pain that. and primary particularly Thank we're in with LVAD, we're pain, action excited with Session commencement and very leave for about towards proposed open of meeting XX inflammatory pivotal IV back our B, endpoint. III approval. in the And much. upcoming a to II, common under reduce Question-and-Answer pathway questions. And the it designation, failure, both month with at of the class FDA unmet with potential I'll
